Treatment of Post-Streptococcal Glomerulonephritis
Treat all patients with post-streptococcal glomerulonephritis (PSGN) with penicillin (or erythromycin if penicillin-allergic) even when active infection has resolved, combined with supportive management of fluid overload and hypertension using diuretics and sodium restriction. 1, 2
Antibiotic Therapy
Administer antibiotics regardless of whether active infection is still present—the goal is to reduce streptococcal antigenic load, not to treat active infection. 1
- First-line: Penicillin for all patients 1, 2
- Penicillin allergy: Erythromycin 1, 2
- Non-anaphylactic penicillin allergy or beta-lactamase producing organisms: First-generation cephalosporins (e.g., cephalexin) 1, 2
- Severe infections or resistant organisms: Third-generation cephalosporins (e.g., ceftriaxone) 1, 2
During community outbreaks, systemic antimicrobials help eliminate nephritogenic strains of Streptococcus pyogenes from the population. 1
Critical pitfall to avoid: Do not withhold antibiotics simply because the pharyngitis or impetigo has clinically resolved—antigenic load reduction is therapeutic even after infection clearance. 1
Supportive Management of Nephritic Syndrome
Sodium and Fluid Management
- Restrict dietary sodium to <2.0 g/day to control hypertension and fluid retention 1, 2
- Monitor fluid status closely and adjust management based on clinical response 1, 2
Blood Pressure Control
- Use diuretics as first-line agents for managing both fluid overload and hypertension 1, 2
- Target blood pressure <130/80 mmHg (or <125/75 mmHg if proteinuria >1 g/day) 2
- ACE inhibitors (captopril, enalapril) provide superior blood pressure control and improved echocardiographic changes compared to other antihypertensives 3
- Nifedipine is effective for acute hypertensive episodes 3
Monitor closely for diuretic-related complications: hyponatremia, hypokalemia, GFR reduction, and volume depletion. 1, 2
Additional Supportive Measures
- Treat metabolic acidosis if serum bicarbonate <22 mmol/L 1, 2
- Consider treating dyslipidemia in patients with nephrotic syndrome, particularly those with other cardiovascular risk factors 1
Dialysis Indications
Provide dialysis for severe acute kidney injury with: 1, 2
- Uremia
- Refractory fluid overload
- Life-threatening hyperkalemia
Immunosuppressive Therapy
Reserve corticosteroids ONLY for severe crescentic PSGN with rapidly progressive glomerulonephritis—evidence is anecdotal at best. 1, 2
- Do NOT use immunosuppression for typical PSGN as the disease is self-limited with excellent prognosis 1
- For most patients with immune complex glomerulonephritis presenting with eGFR <30 ml/min per 1.73 m², supportive care alone is recommended 1
- Combined immunosuppressants for crescentic post-streptococcal glomerulonephritis showed no advantages over supportive therapy alone 3
Critical pitfall: Avoid routine immunosuppression—most cases resolve spontaneously and the evidence for immunosuppression is weak. 1
Monitoring and Follow-Up
Complement Monitoring
- C3 complement levels should normalize within 8-12 weeks in uncomplicated cases 1, 2
- If C3 remains low beyond 12 weeks, perform kidney biopsy to exclude complement C3 glomerulonephritis (C3GN) 1, 2
Regular Assessment
Monitor throughout disease course: 1, 2
- Kidney function (serum creatinine, eGFR)
- Blood pressure
- Urinalysis with microscopy for proteinuria and hematuria
- Urine protein-to-creatinine ratio
Kidney Biopsy Indications
Perform kidney biopsy when: 1
- Diagnosis is uncertain
- Atypical presentation
- Persistently low C3 beyond 12 weeks
- Rapidly progressive glomerulonephritis
Prognosis Considerations
The majority of children with epidemic PSGN have excellent prognosis, contrasting with poorer long-term outcomes in sporadic adult cases. 3 Hypertension during acute phase occurs in approximately 95% of patients but typically resolves within 3-5 days with normalization of glomerular filtration rate and plasma volume. 4 Persistent hypertension beyond the acute phase is a poor prognostic sign and contributes to glomerulosclerosis development. 4